Madison Asset Management LLC Takes $1.94 Million Position in Charles River Laboratories International, Inc. $CRL

Madison Asset Management LLC purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 12,366 shares of the medical research company’s stock, valued at approximately $1,935,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Neo Ivy Capital Management purchased a new position in shares of Charles River Laboratories International during the 2nd quarter worth approximately $29,000. Atlantic Union Bankshares Corp bought a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $31,000. Geneos Wealth Management Inc. grew its stake in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the period. Allworth Financial LP grew its stake in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after purchasing an additional 190 shares during the period. Finally, SJS Investment Consulting Inc. bought a new position in Charles River Laboratories International in the third quarter worth $48,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Down 8.6%

NYSE:CRL opened at $165.57 on Thursday. The stock has a market cap of $8.15 billion, a price-to-earnings ratio of -106.13, a PEG ratio of 5.43 and a beta of 1.63. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The company’s 50 day moving average price is $204.25 and its 200-day moving average price is $179.95. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $228.88.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CRL shares. Evercore upped their target price on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Barclays boosted their price objective on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. JPMorgan Chase & Co. raised their target price on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a report on Monday, December 15th. Finally, Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a research note on Monday, December 1st. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $209.46.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.